{
    "id": 3587,
    "name": "pancreatic ductal carcinoma",
    "source": "DOID",
    "definition": "A pancreatic carcinoma located_in the pancreatic duct. [url:http\\://en.wikipedia.org/wiki/Pancreatic_cancer, url:http\\://en.wikipedia.org/wiki/Pancreatic_duct]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        "10023"
    ],
    "termId": "DOID:3587",
    "evidence": [
        {
            "id": 4448,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CB-839 increased senstivity of KRAS-mutant pancreatic ductal carcinoma cells with NQO1-over expression to ARQ761 in culture, and CB-839 and ARQ761 in combination resulted in decreased tumor growth and extended median survival in NQO1-over expressing KRAS-mutant pancreatic ductal carcinoma cell line xenograft models (PMID: 26462257)",
            "molecularProfile": {
                "id": 18160,
                "profileName": "KRAS mut NQO1 over exp"
            },
            "therapy": {
                "id": 3517,
                "therapyName": "ARQ761 + CB-839",
                "synonyms": null
            },
            "indication": {
                "id": 3587,
                "name": "pancreatic ductal carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4555,
                    "pubMedId": 26462257,
                    "title": "Targeting glutamine metabolism sensitizes pancreatic cancer to PARP-driven metabolic catastrophe induced by \u00df-lapachone.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26462257"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6423,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Emerging",
            "efficacyEvidence": "In a preclinical study, addition of Tarceva (erlotinib) overcame Gemzar (gemcitabine)-resistance in pancreatic ductal carcinoma cell lines with reduced Cbl expression via shRNA, resulted in decreased viability in cell culture and reduced tumor growth in cell line xenograft models (PMID: 25348515).",
            "molecularProfile": {
                "id": 23382,
                "profileName": "CBL dec exp"
            },
            "therapy": {
                "id": 2381,
                "therapyName": "Erlotinib + Gemcitabine",
                "synonyms": null
            },
            "indication": {
                "id": 3587,
                "name": "pancreatic ductal carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5579,
                    "pubMedId": 25348515,
                    "title": "Low expression of the E3 ubiquitin ligase CBL confers chemoresistance in human pancreatic cancer and is targeted by epidermal growth factor receptor inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25348515"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6733,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human pancreatic ductal carcinoma cell lines harboring mutant KRAS were insensitive to Mekinist (trametinib) in culture (PMID: 26343583).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3587,
                "name": "pancreatic ductal carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5709,
                    "pubMedId": 26343583,
                    "title": "Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343583"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14200,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, SBP-101 demonstrated safety and preliminary efficacy, resulted in stable disease in 27.6% (8/29) of patients with pancreatic ductal adenocarcinoma (Journal of Clinical Oncology 36, no. 15_suppl; NCT02657330).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 7037,
                "therapyName": "SBP-101",
                "synonyms": null
            },
            "indication": {
                "id": 3587,
                "name": "pancreatic ductal carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 11506,
                    "pubMedId": null,
                    "title": "A phase 1 safety study of SBP-101, a polyamine metabolic inhibitor, for pancreatic ductal adenocarcinoma (PDA).",
                    "url": "http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.e16231"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT01621243",
            "title": "M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1779,
                    "therapyName": "Gemcitabine + Nab-paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 4251,
                    "therapyName": "Necuparanib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01821729",
            "title": "Proton w/FOLFIRINOX-Losartan for Pancreatic Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1903,
                    "therapyName": "Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin",
                    "synonyms": "FOLFIRINOX|FOLFOXIRI"
                },
                {
                    "id": 2998,
                    "therapyName": "Losartan",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02452424",
            "title": "A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 2736,
                    "therapyName": "Pembrolizumab + Pexidartinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02558894",
            "title": "Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1356,
                    "therapyName": "Durvalumab",
                    "synonyms": null
                },
                {
                    "id": 1652,
                    "therapyName": "Tremelimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02646748",
            "title": "Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 7159,
                    "therapyName": "Itacitinib + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 8295,
                    "therapyName": "Parsaclisib + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04177810",
            "title": "Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 9002,
                    "therapyName": "Cemiplimab + Plerixafor",
                    "synonyms": null
                }
            ]
        }
    ]
}